European pharmaceutical companies have warned EU ... says Nahyan bin Mubarak at IPSC 2025 Dubai [UAE], April 13 (ANI/WAM): The UAE, thanks to its visionary leadership and advanced infrastructure ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Clearly, options traders are pricing in a big move for ANI Pharmaceuticals shares, but what is the fundamental picture for the company? Currently, ANI Pharmaceuticals is a Zacks Rank #1 (Strong ...

Truist analyst Les Sulewski raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $65 from $62 and keeps a Hold rating on the shares ...

ANI Pharmaceuticals projects 2025 revenue between $756 million and $776 million. The rare disease segment, including Cortrophin Gel, is a major growth driver. ILUVIEN and YUTIQ, acquired from ...

Even during a down period for the markets, ANI Pharmaceuticals has gone against the grain, climbing to $68.06. Its shares have yielded a 16.1% return over the last six months, beating the S&P 500 by ...

ANI Pharmaceuticals has a 12 month low of $52.50 and a 12 month high of $70.00. The stock has a market capitalization of $1.44 billion, a P/E ratio of -120.02 and a beta of 0.49.

In a report released today, Vamil Divan from Guggenheim reiterated a Buy rating on ANI Pharmaceuticals (ANIP – Research Report), with a price ...

Has ANI Pharmaceuticals (ANIP) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is ANI Pharmaceuticals (ANIP) one of those stocks right now? A ...